# Age Related Macular Degeneration Market

> Marché de la dégénérescence maculaire liée à l'âge : informations par type (dégénérescence maculaire humide liée à l'âge (DMLA humide) et dégénérescence maculaire liée à l'âge sec (DMLA sèche)) stade (dégénérescence maculaire liée à l'âge au stade intermédiaire, dégénérescence maculaire liée à l'âge à un stade précoce et dégénérescence maculaire liée à l'âge à un stade avancé) Groupe d'âge (plus de 75 ans, plus de 60 ans et plus de 40 ans) par traitement (traitement et diagnostic) Voie d'administration (voie d'administration intravitréenne et voie d'administration intraveineuse) Utilisateur final (hôpitaux et cliniques, centres de diagnostic et instituts de recherche universitaires) et région - Prévisions jusqu'en 2030

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.43%
- **2024:** $ 8.45 Billion
- **2025:** $ 9.16 Billion
- **2035:** $ 20.59 Billion
- **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche(CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP)

**Report ID:** MRFR/Pharma/4281-CR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

---

## Market Summary

As per Market Research Future analysis, the Age-Related Macular Degeneration Market Size was estimated at 8.45 USD Billion in 2024. The Age-Related Macular Degeneration industry is projected to grow from 9.163 USD Billion in 2025 to 20.59 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.43% during the forecast period 2025 - 2035

## Market Drivers

### Advancements in Treatment Modalities

Innovations in treatment modalities for Age-Related Macular Degeneration are driving the Age-Related Macular Degeneration Market forward. Recent advancements include the development of novel pharmacological agents, such as anti-VEGF therapies, which have shown promising results in clinical trials. These therapies are designed to inhibit the growth of abnormal blood vessels in the retina, thereby slowing disease progression. Additionally, the introduction of gene therapy and stem cell treatments offers potential new avenues for AMD management. The market is witnessing a surge in clinical trials aimed at evaluating these innovative therapies, which could lead to improved patient outcomes and increased market share for companies involved in the Age-Related Macular Degeneration Market.

### Regulatory Support and Policy Initiatives

Regulatory support and favorable policy initiatives are emerging as key drivers for the Age-Related Macular Degeneration Market. Governments and regulatory bodies are increasingly recognizing the burden of AMD on public health and are implementing policies to facilitate the approval of new therapies. Streamlined regulatory pathways and incentives for research and development are encouraging companies to invest in AMD-related projects. Additionally, reimbursement policies that support the use of innovative treatments are likely to enhance patient access to care. This supportive regulatory environment is expected to stimulate growth in the Age-Related Macular Degeneration Market, as it encourages the development and commercialization of new therapeutic options.

### Growing Awareness and Screening Initiatives

The rise in awareness regarding Age-Related Macular Degeneration is significantly influencing the Age-Related Macular Degeneration Market. Public health campaigns and educational initiatives are increasingly emphasizing the importance of early detection and regular eye examinations. As awareness grows, more individuals are likely to seek screening for AMD, leading to earlier diagnosis and treatment. This trend is supported by various organizations advocating for eye health, which has resulted in increased funding for screening programs. Consequently, the heightened focus on AMD awareness is expected to drive demand for diagnostic tools and treatment options, thereby positively impacting the Age-Related Macular Degeneration Market.

### Increased Investment in Research and Development

Investment in research and development within the Age-Related Macular Degeneration Market is on the rise, driven by the urgent need for effective therapies. Pharmaceutical companies and research institutions are allocating substantial resources to explore new treatment options and improve existing therapies. This trend is evidenced by the growing number of clinical trials focused on AMD, which have increased significantly in recent years. The commitment to R&D is likely to yield innovative solutions that address unmet medical needs, thereby enhancing the competitive landscape of the Age-Related Macular Degeneration Market. Furthermore, collaborations between academia and industry are fostering an environment conducive to breakthroughs in AMD treatment.

### Rising Prevalence of Age-Related Macular Degeneration

The increasing prevalence of Age-Related Macular Degeneration (AMD) is a primary driver for the Age-Related Macular Degeneration Market. As populations age, the incidence of AMD is expected to rise significantly. According to recent estimates, nearly 196 million individuals are projected to be affected by AMD by 2020, with numbers expected to reach 288 million by 2040. This growing patient population necessitates the development and availability of effective treatment options, thereby propelling market growth. Furthermore, the aging demographic is likely to increase the demand for healthcare services and interventions related to AMD, which in turn stimulates investment in research and development within the Age-Related Macular Degeneration Market.

## Future Outlook

The Age-Related Macular Degeneration Market is projected to grow at an 8.43% CAGR from 2025 to 2035, driven by increasing aging populations, advancements in treatment options, and rising awareness.

**New opportunities:**

- Development of telemedicine platforms for remote patient monitoring Investment in gene therapy research for AMD treatment Expansion of personalized medicine approaches in AMD management

By 2035, the market is expected to be robust, driven by innovative treatments and increased patient engagement.

## Segment Insights

### By Type: Dry Age-Related Macular Degeneration (Largest) vs. Wet Age-Related Macular Degeneration (Fastest-Growing)

In the Age-Related Macular Degeneration (AMD) market, Dry Age-Related Macular Degeneration holds the largest market share, primarily due to its higher prevalence compared to the wet type. As a condition that typically develops slowly and can lead to gradual vision loss, it accounts for a significant proportion of AMD cases. In contrast, Wet Age-Related Macular Degeneration, though less common, is rapidly gaining attention due to its severe impact on vision, thus driving its market presence.

Wet Age-Related Macular Degeneration (Dominant) vs. Geographic Atrophy (Emerging)

Wet Age-Related Macular Degeneration is characterized by the growth of abnormal blood vessels beneath the retina, leading to potential rapid vision loss. This segment dominates the AMD market due to its urgent treatment needs and effective therapeutic innovations. In comparison, Geographic Atrophy, while recognized as an emerging segment, poses ongoing challenges in treatment and awareness. However, its increasing identification as a significant condition in AMD is creating opportunities for research and development, hinting at a gradual rise in its market status.

### By Treatment Method: Anti-VEGF Therapy (Largest) vs. Photodynamic Therapy (Fastest-Growing)

The Age-Related Macular Degeneration Market is primarily dominated by Anti-VEGF Therapy, which holds the largest share among treatment methods due to its proven efficacy in slowing disease progression. Photodynamic Therapy follows as a strong contender, showcasing significant growth in recent years owing to advancements in technology and increasing awareness. Laser Surgery and Nutritional Supplements, while vital components of treatment, occupy smaller market shares, indicating a more conservative adoption in comparison to the primary therapies.

Anti-VEGF Therapy (Dominant) vs. Photodynamic Therapy (Emerging)

Anti-VEGF Therapy remains the dominant choice in the Age-Related Macular Degeneration Market, primarily for its significant impact on slowing the progression of wet AMD. With continuous innovations and the introduction of new formulations, its relevance is expected to persist. In contrast, Photodynamic Therapy is emerging as a viable alternative, especially for patients who are resistant to traditional treatments. This method leverages light-activated compounds to target abnormal [blood](https://www.marketresearchfuture.com/reports/blood-collection-tube-market-42299)vessels in the retina, providing a minimally invasive option with promising results. As awareness and research grow, Photodynamic Therapy is positioned to capture an expanding share of the market.

### By Distribution Channel: Hospitals (Largest) vs. Optical Clinics (Fastest-Growing)

In the Age-Related Macular Degeneration Market, distribution channels play a vital role in delivering treatment options to patients. Hospitals are currently the largest segment, accounting for a significant share of product sales. Their established reputation in providing comprehensive care and access to various treatments positions them as the foremost choice for patients suffering from this degenerative eye condition. However, Optical Clinics are emerging rapidly, not only offering specialized services but also enhancing patient accessibility in a more focused environment.

Hospitals (Dominant) vs. Optical Clinics (Emerging)

Hospitals, with their extensive infrastructure and multidisciplinary teams, dominate the distribution channels for Age-Related Macular Degeneration treatments. They offer a wide array of therapeutic options, ensuring that patients receive the most appropriate care. On the other hand, Optical Clinics have gained momentum, emerging as a significant competitor due to their personalized [services](https://www.marketresearchfuture.com/reports/anti-aging-services-market-7579) and the convenience they provide. They attract patients seeking specialized care away from the hospital environment, making treatments more accessible and often more affordable. As awareness of age-related macular degeneration grows, Optical Clinics are likely to enhance their market position further, capitalizing on the trend towards outpatient care.

### By Patient Demographics: Elderly Patients (Largest) vs. Middle-Aged Patients (Fastest-Growing)

In the Age-Related Macular Degeneration (AMD) market, the distribution of patient demographics reveals that elderly patients represent the largest share due to their increased vulnerability to this condition. This demographic often experiences significant vision impairment leading to a high demand for treatment and care. Meanwhile, middle-aged patients are emerging as a fast-growing segment as more people in their 40s and 50s are being diagnosed, prompting early intervention strategies to combat potential vision loss.

Patient Type: Elderly Patients (Dominant) vs. Middle-Aged Patients (Emerging)

Elderly patients are currently the dominant demographic in the AMD market due to the natural age-related decline in vision, making them more susceptible to macular degeneration. This group often prefers established treatment options and is more likely to seek medical advice, contributing to their significant market presence. In contrast, middle-aged patients represent an emerging segment. Their increasing diagnosis rates are driven by lifestyle factors and genetic predispositions, prompting a shift in focus towards early detection and preventative measures. Innovative treatments tailored for this younger demographic are becoming essential as they seek to maintain their visual health into later years.

## Regional Market Share Analysis

The Age-Related Macular Degeneration Market exhibits significant growth across various regions. In 2024, the market is set to be valued at 8.89 USD Billion, reflecting the substantial demand for treatment and management solutions for this prevalent condition. North America leads this market with a valuation of 3.56 USD Billion in 2024, projected to rise to 6.48 USD Billion by 2035, driven by advanced healthcare infrastructure and higher healthcare spending.

Europe follows with a market valuation of 2.75 USD Billion in 2024, and expected to reach 4.92 USD Billion by 2035, indicating its strong healthcare systems and growing awareness.In South America, the market is expected to grow from 0.67 USD Billion in 2024 to 1.19 USD Billion in 2035, reflecting an emerging need for age-related healthcare solutions. Asia Pacific showcases substantial potential as well, starting at 1.88 USD Billion in 2024 and anticipated to expand to 3.39 USD Billion by 2035, driven by a rapidly aging population.

Lastly, the Middle East and Africa is projected to grow from 0.89 USD Billion in 2024 to 1.62 USD Billion by 2035, highlighting the increasing focus on healthcare development in these regions.This regional analysis demonstrates the diverse market landscape for the Age-Related Macular Degeneration Market, with varying growth drivers and healthcare dynamics influencing each area.

## Competitive Benchmarking

The Age-Related Macular Degeneration Market is characterized by a rapidly evolving competitive landscape, primarily driven by the increasing prevalence of age-related macular degeneration (AMD), along with advancements in treatment options and a growing elderly population. The market dynamics are influenced by various factors, including innovation in drug development, regulatory changes, and the introduction of cutting-edge technologies. Companies operating within this space are constantly striving to capture market share and meet the rising demand for effective therapies. As businesses expand their product portfolios and strengthen their research and development initiatives, unique competitive advantages are formed, positioning players differently in the market. The collaboration between industry stakeholders, such as pharmaceutical companies, research institutions, and healthcare providers, further enhances the competitive insight, fostering an environment of continual growth and adaptation.Regeneron [Pharmaceutical Industry](https://www.marketresearchfuture.com/reports/pharmaceutical-industry-market-43636) has established itself as a leading player in the Age-Related Macular Degeneration Market with a well-founded reputation for innovation and efficacy in its product offerings. The company's strength lies in its robust pipeline of advanced treatments, particularly its pioneering therapies for wet AMD, which have achieved significant clinical success. Regeneron's commitment to research and relentless pursuit of improving patient outcomes allows it to maintain a competitive edge. Furthermore, its strategic collaborations, partnerships, and investments in biotechnology enable the company to stay ahead in an increasingly competitive environment. The development of cutting-edge treatment modalities, combined with excellent brand recognition and strong clinical data, solidifies Regeneron's position in the global market, showcasing its role as a formidable competitor.Novartis also plays a significant role in the Age-Related Macular Degeneration Market, recognized for its extensive portfolio that addresses the diverse needs of AMD patients. The company is renowned for its innovative therapies, which encompass both established and emerging treatments aimed at managing various forms of AMD. Novartis has reinforced its market presence through strategic mergers and acquisitions, enhancing its ability to deliver high-quality services and products. The company's strengths are also evident in its commitment to research and development, which enables Novartis to introduce novel therapies and maintain a competitive advantage. Moreover, Novartis engages in collaborations with healthcare systems and academic institutions, facilitating advancements in treatment approaches. Their emphasis on patient-centered solutions and a comprehensive product portfolio further augments their position in the global arena, allowing them to maintain leadership in the age-related macular degeneration therapeutics landscape.

## Recent News & Developments

In recent months, the Age-Related Macular Degeneration Market has seen significant activity and developments. Companies such as Regeneron Pharmaceuticals and Novartis continue to lead in therapeutic innovation, with strides in anti-VEGF treatments improving patient outcomes. Bayer is also pushing forward with clinical trials aimed at developing novel therapies. In terms of mergers and acquisitions, Roche announced a strategic acquisition of a leading biotechnology firm focused on eye disease in November 2023, which aims to bolster its portfolio in the AMD space.

Over the past two years, significant efforts in Research and Development across the sector indicate a clear focus on enhancing both treatment options and patient care, driving a substantial upward trajectory in market growth and investment. Collaborative initiatives among these companies also hint at increasing partnerships to innovate solutions for age-related eye diseases globally.

## Report Scope

| MARKET SIZE 2024 | 8.45(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.163(USD Billion) |
| MARKET SIZE 2035 | 20.59(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.43% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP) |
| Segments Covered | Types, Treatment Method, Distribution Channel, Patient Demographics, Regional |
| Key Market Opportunities | Advancements in gene therapy and digital health solutions enhance treatment options in the Age-Related Macular Degeneration Market. |
| Key Market Dynamics | Rising prevalence of Age-Related Macular Degeneration drives demand for innovative treatment options and advanced diagnostic technologies. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Age-Related Macular Degeneration by 2035?**
A: The projected market valuation for Age-Related Macular Degeneration is expected to reach 20.59 USD Billion by 2035.

**Q: What was the market valuation for Age-Related Macular Degeneration in 2024?**
A: The overall market valuation for Age-Related Macular Degeneration was 8.45 USD Billion in 2024.

**Q: What is the expected CAGR for the Age-Related Macular Degeneration market from 2025 to 2035?**
A: The expected CAGR for the Age-Related Macular Degeneration market during the forecast period 2025 - 2035 is 8.43%.

**Q: Which treatment method is projected to have the highest market value by 2035?**
A: Anti-VEGF Therapy is projected to have the highest market value, expected to grow from 3.5 USD Billion to 8.5 USD Billion.

**Q: What are the key players in the Age-Related Macular Degeneration market?**
A: Key players in the market include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Alcon, Horizon Therapeutics, Apellis Pharmaceuticals, and Santen Pharmaceutical.

**Q: How does the market for Dry Age-Related Macular Degeneration compare to Wet Age-Related Macular Degeneration?**
A: The market for Dry Age-Related Macular Degeneration is expected to grow from 3.38 USD Billion to 8.0 USD Billion, while Wet Age-Related Macular Degeneration is projected to increase from 4.23 USD Billion to 9.8 USD Billion.

**Q: What distribution channel is anticipated to show significant growth by 2035?**
A: Online Pharmacies are anticipated to show significant growth, with a projected increase from 2.12 USD Billion to 5.3 USD Billion.

**Q: Which patient demographic is expected to dominate the Age-Related Macular Degeneration market?**
A: Elderly Patients are expected to dominate the market, with a projected growth from 3.5 USD Billion to 8.5 USD Billion.

**Q: What is the expected market value for Nutritional Supplements by 2035?**
A: The expected market value for Nutritional Supplements is projected to rise from 2.45 USD Billion to 6.09 USD Billion by 2035.

**Q: How does the market for Optical Clinics compare to Retail Pharmacies in terms of growth?**
A: The market for Optical Clinics is expected to grow from 1.69 USD Billion to 4.05 USD Billion, whereas Retail Pharmacies are projected to increase from 2.12 USD Billion to 5.12 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736*